semaglutide derived from Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity Weight loss with semaglutide reduces

While both medications activate GLP-1 receptors to reduce appetite and enhance satiety, semaglutide is simply a more potent and longer-acting molecule

Just as described

Semaglutide works by reducing blood sugar levels, slowing the digestion of food, and decreasing hunger, leading to weight loss over time

Exercise caution in patients with a history of pancreatitis

Oral #Wegovy Approved in Europe The European Medicines Agency (EMA) granted approval for once-daily oral semaglutide (the Wegovy tablet) for the treatment of obesity and overweight, making it the first oral GLP-1 treatment for weight management authorised in the European Union